Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Completed 37Terminated 18Unknown 11Recruiting 4Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4CNS 1

Conditions

Glioblastoma 45Glioma 16Neuroblastoma 15Brain Neoplasms 14Astrocytoma 10Neoplasms 8Rhabdomyosarcoma 7Sarcoma, Ewing 6Recurrence 5Oligodendroglioma 5Medulloblastoma 5Sarcoma 4Osteosarcoma 4Melanoma 4Small Cell Lung Carcinoma 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Lymphoma 3Gliosarcoma 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Rhabdoid Tumor 2Pyloric Stenosis, Hypertrophic 2Ovarian Neoplasms 2Neoplasm Metastasis 2Ganglioneuroblastoma 2Fallopian Tube Neoplasms 2Ependymoma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2

Interventions

pembrolizumab 54Nivolumab 51Ipilimumab 29Cyclophosphamide 16binimetinib 10Specimen Handling 10Magnetic Resonance Spectroscopy 10fludarabine 9Radiosurgery 9relatlimab 8encorafenib 8Opdualag 8Interleukin-2 8Biopsy 8aldesleukin 7Blood Specimen Collection 7atezolizumab 6Immunotherapy 6cemiplimab 5CTLA-4 Antigen 5Bevacizumab 5trametinib 4dabrafenib 4Temozolomide 4Paclitaxel 4Immune Checkpoint Inhibitors 4spartalizumab 3fludarabine phosphate 3Surgical Procedures, Operative 3Metformin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Melanoma × Temozolomide × Clear all
NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

NCT05588453 2026-01-12

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT06703398 2025-12-23

MIZAR-003

Shanghai Juncell Therapeutics

Phase 2 Recruiting
98 enrolled
Dermatologic

Melanoma

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
60 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡